Italy to India Pharmaceutical Import

The pharmaceutical trade corridor between Italy and India has experienced significant growth over the past decade. In 2022, the total import value stood at $471.9 million USD, with 1,710 shipments from 133 Italian suppliers to 88 Indian buyers. This reflects a robust and expanding trade relationship, underscoring Italy's increasing role in supplying pharmaceutical products to the Indian market.

Key milestones in this evolution include the establishment of streamlined regulatory processes and enhanced logistical frameworks. The introduction of the CDSCO's SUGAM portal in 2016 facilitated more efficient registration and approval procedures for foreign pharmaceutical companies, including those from Italy. This digitalization has significantly reduced processing times and improved transparency in the import process.

Italy has become a significant contributor to India's pharmaceutical imports, with a total import value of $471.9 million USD over the past five years. The top 10 imported products from Italy include valsartan ($103.0 million, 21.8%), serum ($84.5 million, 17.9%), insulin ($78.0 million, 16.5%), and prednisolone ($57.5 million, 12.2%). These products highlight Italy's strength in supplying essential medications, particularly in the cardiovascular and endocrine therapeutic areas.

Italian pharmaceutical companies such as Pfizer Service Company BV, Takeda Pharmaceuticals International AG, and Novartis Pharma AG have been instrumental in this trade, supplying a diverse range of products to meet India's growing healthcare needs. Their consistent presence underscores the trust and demand for Italian pharmaceutical products in the Indian market.

Between 2024 and 2026, several developments have influenced the Italy-India pharmaceutical trade corridor. The CDSCO has implemented policy changes to streamline the registration process for foreign pharmaceutical companies, including those from Italy. The SUGAM portal has been enhanced to support electronic submissions, reducing processing times and improving transparency.

Additionally, trade agreements between India and the European Union have been under negotiation, aiming to reduce tariffs and non-tariff barriers. These agreements are expected to further facilitate the import of pharmaceutical products from Italy to India, promoting a more integrated and efficient trade relationship.

Italian pharmaceutical companies seeking to export products to India must navigate the CDSCO's registration process. The first step involves registering on the SUGAM portal, where applicants must provide details such as the Corporate Identification Number (CIN), Customs House Agent (CHA) information, and authorized personnel details. Required documents include an undertaking form, valid address proof of the firm (e.g., Certificate of Incorporation, GST Certificate), and a valid ID proof of the authorized person.

Once registered, companies can submit applications for import licenses using Form 8, accompanied by an undertaking in Form 9. The CDSCO reviews these applications to ensure compliance with Indian regulations. For products requiring clinical trials, additional documentation such as clinical trial data and ethical committee approvals are necessary.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practices (GMP) standards as outlined by the World Health Organization (WHO). Italian manufacturers must provide a GMP certificate issued by the National Regulatory Authority of their country, ensuring that their facilities meet international quality standards. The CDSCO may conduct inspections to verify compliance with these standards.

To import pharmaceutical products into India, Italian companies must obtain an import license (Form 10) from the CDSCO. This requires submitting a registration certificate, a No Objection Certificate (NOC) from the CDSCO, a test license, and adhering to customs procedures. The SUGAM portal facilitates the submission of these documents, streamlining the approval process.

India's pharmaceutical imports from Italy are predominantly in the form of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The top 10 imported products reflect a strong demand for cardiovascular drugs like valsartan, endocrine therapies such as insulin and prednisolone, and biologics like serum. This trend indicates Italy's specialization in supplying high-quality, essential medications that complement India's domestic production capabilities.

Italian pharmaceutical companies are known for their innovative approaches, offering novel formulations and advanced therapies not yet manufactured domestically in India. Products like teicoplanin, a glycopeptide antibiotic, and canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor for diabetes, exemplify Italy's contribution to India's healthcare sector by providing specialized treatments that address specific medical needs.

India's import demand from Italy is driven by several factors, including the need for patented drugs not available locally, technological advancements in pharmaceutical manufacturing, and stringent quality requirements. The high disease burden in India, particularly in areas like cardiovascular diseases and diabetes, further propels the demand for effective treatments, many of which are supplied by Italian pharmaceutical companies.

India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. These duties are subject to change based on government policies and trade agreements. Pharmaceutical imports from Italy are typically classified under specific HS codes, which determine the applicable duty rates. Importers should consult the latest customs notifications and the Directorate General of Foreign Trade (DGFT) guidelines for accurate and up-to-date information.

India and Italy, as part of the European Union, are engaged in trade agreements aimed at reducing tariffs and non-tariff barriers. These agreements are expected to facilitate the import of pharmaceutical products from Italy to India by providing preferential duty rates and streamlining customs procedures. The Regional Comprehensive Economic Partnership (RCEP) and other bilateral negotiations also play a role in shaping the trade dynamics between the two countries.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the granting of compulsory licenses under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported formulations, to ensure affordability. Imported drugs are subject to price controls, which can impact the pricing strategies of Italian pharmaceutical companies exporting to India.

Pharmaceutical products from Italy to India are primarily transported via sea and air routes. Major Italian export ports include Genoa and Naples, while Indian import ports handling pharmaceutical shipments include Mumbai, Chennai, and Kolkata. Sea freight typically takes 20-30 days, depending on the shipping line and route, while air freight is faster, usually taking 5-7 days. The reliability of these routes is generally high, with established shipping lines and air cargo services ensuring timely deliveries.

Italian export ports like Genoa and Naples are well-equipped to handle pharmaceutical exports, offering facilities that comply with international shipping standards. In India, ports such as Mumbai, Chennai, and Kolkata have dedicated terminals for pharmaceutical imports, equipped with cold storage facilities to maintain the integrity of temperature-sensitive products. These ports adhere to the guidelines set by the Directorate General of Shipping and the Directorate General of Foreign Trade (DGFT) to ensure efficient handling and clearance of pharmaceutical shipments.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance procedures, which include documentation verification, inspection, and testing by the CDSCO to ensure compliance with Indian regulations. Cold chain management is critical for temperature-sensitive products; therefore, importers must ensure that shipments are accompanied by a valid Certificate of Analysis and comply with the Good Distribution Practice (GDP) guidelines. The CDSCO may conduct inspections to verify compliance with these standards, and any discrepancies can lead to delays or rejections of shipments.

Despite being a major manufacturer of generic pharmaceuticals, India imports a significant portion of its pharmaceutical requirements from Italy. This dependency is largely due to the need for patented drugs, advanced biologics, and specialized formulations that are not yet produced domestically. Italy's strong pharmaceutical industry, characterized by innovation and high-quality standards, positions it as a key supplier to meet these specific needs in the Indian market.

Major Italian pharmaceutical companies, such as Pfizer Service Company BV, Takeda Pharmaceuticals International AG, and Novartis Pharma AG, have established a strong presence in India. These companies employ strategies like direct exports, partnerships with local